SCHEMBL1717465

SCHEMBL1717465

CC[C@H](NC(=O)c1c(C)n(-c2cccc(OC)c2)c(=O)c2ccccc12)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 14/20 0.51
TACR2 P21452 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
USP2 O75604 1/20 0.45
RAB9A P51151 1/20 0.44
KCNA5 P22460 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2D6 P10635 1/20 0.44
TACR1 P25103 1/20 0.44
OPRM1 P35372 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
MAPK1 P28482 1/20 0.44
BLM P54132 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1716958 0.90 TACR3 (0.56) TACR3TACR2SMN1; SMN2KCNA5CYP1A2
SCHEMBL1717845 0.89 TACR3 (0.46) TACR3TACR2SMN1; SMN2CYP1A2CYP3A4
SCHEMBL1717011 0.89 TACR3 (0.51) TACR3TACR2SMN1; SMN2CYP1A2CYP3A4
SCHEMBL1717742 0.88 TACR3 (0.47) TACR3TACR2SMN1; SMN2CYP1A2CYP3A4
SCHEMBL1717597 0.88 TACR3 (0.49) TACR3TACR2SMN1; SMN2USP2RAB9A
SCHEMBL1717247 0.87 TACR3 (0.55) TACR3TACR2SMN1; SMN2CYP1A2CYP3A4
SCHEMBL1717256 0.84 TACR3 (0.48) TACR3TACR2SMN1; SMN2KCNA5CYP1A2
SCHEMBL1717512 0.83 TACR3 (0.46) TACR3TACR2SMN1; SMN2CYP1A2CYP3A4
SCHEMBL1716833 0.83 TACR3 (0.52) TACR3TACR2SMN1; SMN2CYP1A2CYP3A4
SCHEMBL1717691 0.82 TACR3 (0.54) TACR3TACR2SMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 TACR3 30/4885TACR2 31/4885SMN1; SMN2 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.